Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DWRX2003 in COVID-19
NCT04541485Phase 1Terminated
- Sponsor
- Daewoong Pharmaceutical
- Start
- Dec 2020
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of niclosamide in coronavirus disease 2019 (COVID-19) (5 cohorts), sponsored by Daewoong Pharmaceutical. Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 42 days. Started Dec 2020; status: terminated.
02
Drugs
niclosamide
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04541485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04541485.